) to buy from hold.
Analyst Ryan Rauch tells Standard & Poor's MarketScope he believes the Image-Guided Radiotherapy Technology (IGRT) cycle is real. He says the company recently said it expects to report 19% worldwide oncology growth, vs. his ll% estimate. Rauch notes 61% of respondents from a survey indicated they plan to buy IGRT upgrades or IGRT-ready machines within the next 12 months. The analyst notes the majority of those that plan to buy IGRT upgrades indicated the supplier would be Varian.